Posts filed under: Pharmaceuticals

Register to receive a free Global Immunology Drugs Market Report Suite 2018-2024 report synopsis and brochure Did you know that 46 new drugs and biological products were approved by the FDA in 2017 alone?1 This is more than double the number approved...
Continue Reading →
Register to receive a free Global Immunology Drugs Market Report Suite 2018-2024 report synopsis and brochure A new study by iData Research estimates that there are nearly 150,000 new cases of psoriasis (PsO) every year in the United States, affecting 2.2% of the population....
Continue Reading →
Register to receive a free Global Immunology Drugs Market Report Suite 2018-2024 report synopsis and brochure In a new series of reports by iData Research, it was revealed that in 2017, the U.S. immunology market was valued at over $34 billion. A...
Continue Reading →
Register to receive a free Immunology Drugs Market for the US 2018-2024 report synopsis and brochure SetPoint Medical has launched a pilot trial to assess the safety and efficacy of a bioelectronics device in patients, who are suffering from rheumatoid arthritis and...
Continue Reading →
Overall, the U.S. immunology drug market is projected to exceed an estimated $38 billion by 2023 due to the entry of new biosimilars and JAK inhibitors into the market....
Continue Reading →
EADV is a non-profit association whose mission is to advance excellence in clinical care, research, education and training in the fields of Dermatology and Venereology....
Continue Reading →
Biosimilars are, as the name would suggest, highly similar and are a more affordable alternative to biologics that is poised to influence the current dynamics of the immunology market. ...
Continue Reading →
The U.S. immunology drug market is expected to grow to $68 billion by 2023 due to the entry of new biosimilars and JAK inhibitors....
Continue Reading →
Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our biosimilar rituximab matches the reference medicine in terms of safety, efficacy and quality...
Continue Reading →
Agreements Provide Non-Exclusive License to Amgen for HUMIRA-Related Intellectual Property in the U.S. Effective Jan. 31, 2023, And in Other Markets on Different Dates...
Continue Reading →
close-link
close-link
close-link

Subscribe to MedTech Market News - Get exclusive analyst articles, monthly newsletters and iData offers

close-link
close-link
close-link